Andrea Necchi, Associate Editor at Journal of Clinical Oncology, shared a post by Stephen Williams, Associate Chief Medical Officer at The University of Texas Medical Branch, adding:
“Proud to present the data from SunRISe2 trial.
Key takeaways:
- The first R3 trial testing newer therapy vs chemoRT was negative
- This means we should carefully consider chemoRT whenever it comes to a bladder-sparing approach for patients with MIBC
- However, GemiDRS+CET provided evidence for a possible alternative consolidating approach in pts refusing/being ineligible for ChemoRT
- de-escalation strategies for Systemic therapy post major Response to induction therapy will represent a new opportunity
Quoting Stephen Williams‘s post.”
Other articles featuring Andrea Necchi and Stephen Williams on OncoDaily.
